You just read:

Neurocrine Biosciences Announces FDA Approval of Once-Daily ONGENTYS® (opicapone) as an Add-On Treatment for Patients with Parkinson's Disease Experiencing "Off" Episodes

News provided by

Neurocrine Biosciences, Inc.

Apr 27, 2020, 07:30 ET